A5059594543- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Biosimilars and Bioanalytical Methods
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Viral Infectious Diseases and Gene Expression in Insects
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Immune Cell Function and Interaction
- COVID-19 and healthcare impacts
- Childhood Cancer Survivors' Quality of Life
- Cytomegalovirus and herpesvirus research
- Biomedical Ethics and Regulation
- Virus-based gene therapy research
- Epigenetics and DNA Methylation
- Cancer-related gene regulation
- COVID-19 Clinical Research Studies
- Polyomavirus and related diseases
- Renal Transplantation Outcomes and Treatments
- Advancements in Semiconductor Devices and Circuit Design
- Cancer Genomics and Diagnostics
- Integrated Circuits and Semiconductor Failure Analysis
- Monoclonal and Polyclonal Antibodies Research
- Silicon Carbide Semiconductor Technologies
Vall d'Hebron Hospital Universitari
2016-2025
Hebron University
2025
Universitat Autònoma de Barcelona
2017-2024
Vall d'Hebron Institute of Oncology
2018-2024
Vall d'Hebron Institut de Recerca
2023
Universidade Federal de São Carlos
2023
Fundación Pethema
2011-2013
International Society for Heart and Lung Transplantation
2011
National Heart Lung and Blood Institute
2011
European Society for Blood and Marrow Transplantation
2011
Abstract Cytopenias represent the most common side effect of CAR T-cell therapy (CAR-T) and can predispose for severe infectious complications. Current grading systems, such as Common Terminology Criteria Adverse Events (CTCAE), neither reflect unique quality post–CAR-T neutrophil recovery, nor do they inherent risk infections due to protracted neutropenia. For this reason, a novel EHA/EBMT consensus was recently developed Immune Effector Cell-Associated HematoToxicity (ICAHT). In...
COVID-19 is posing a significant threat to health in vulnerable patients, such as immunocompromised patients.For hematopoietic cell transplantation (HCT) recipients and patients with hematologic malignancies it known that leads severe morbidity high mortality compared the general population [1][2][3].For treated Chimeric Antigen Receptor T-cell (CAR-T-cell) therapy for B-cell however, descriptions of clinical course outcome are still limited small case series reports...
Prolonged cytopenias after chimeric antigen receptor (CAR) T cell therapy are a significant clinical problem and the underlying pathophysiology remains poorly understood. Here, we investigated how expansion dynamics serum proteomics affect neutrophil recovery phenotypes CD19-directed CAR therapy. Survival favored patients with "intermittent" (e.g., recurrent dips) compared to either "quick" or "aplastic" recovery. While intermittent displayed increased expansion, aplastic exhibited an...
Abstract Optimal post-remission therapy for adolescents and young adults (AYAs) with Ph-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is not established. We compared overall survival (OS), disease-free (DFS), relapse, non-relapse mortality (NRM) patients receiving on CALGB 10403 to a cohort undergoing myeloablative (MA) allogeneic hematopoietic cell transplantation (HCT) CR1. In univariate analysis, OS was superior chemotherapy MA HCT (3-year 77% vs. 53%, P...
Chimeric antigen receptor T-cell therapy (CAR-T) is an effective approach for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). However, some rare variants do not seem to respond as well this redirecting strategy. T-cell/histiocyte-rich (THRLBCL) infrequent subtype of LBCL which typically develops in young, male patients, characterized by aggressive clinical course and chemo-refractory disease.1, 2 THRLBCL has unique biological characteristics a inhibitory tumor immune...
Abstract COVID-19 has been associated with high mortality in patients treated Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome improved over time primary objective of assessing COVID-19-attributable Omicron period 2022 compared to previous years. Data this multicenter study were collected using MED-A and report forms developed by EBMT. One-hundred-eighty included analysis, 39 diagnosed 2020, 35 2021 106 2022. The median...
SARS-CoV-2 infection has bimodal distribution in Europe with a first wave March to June 2020 and second September February 2021. We compared the frequency, clinical characteristics outcomes of adults acute lymphoblastic leukemia (ALL) vs. pandemic waves Spain.In this prospective study ALL COVID-19 infection, comorbidities, treatment outcome two periods were compared. The ended when vaccination against was implemented Spain.Twenty eight patients collected 24 second. median age 46.5 years...
Adoptive cell therapy using virus‐specific T cells (VST) is a strategy for treating common opportunistic viral infections after transplantation, particularly when these do not resolve through antiviral drug therapy. The availability of third‐party healthy donors allows the immediate use allogeneic in cases where patients lack an appropriate donor. Here, we present creation donor registry human leukocyte antigen (HLA)‐typed blood donors, REDOCEL, strategic initiative to ensure compatible...
Abstract Objectives Our aim was to describe the frequency and severity of infectious complications after chimeric antigen receptor (CAR) T‐cell therapy in patients with large B‐cell lymphoma (LBCL). Methods We retrospectively reviewed clinical records LBCL treated CD19‐targeted CAR from July/2018 December/2021 at our institution, identified all episodes infusion until disease progression, death or last follow‐up. Results Overall, 137 were included. Thirty six percent had received ≥3 previous...
Abstract The potential role of active CMV infection in promoting acute Graft‐versus‐Host Disease (aGvHD) allogeneic hematopoietic stem cell transplantation (allo‐HSCT) remains a matter debate. We further addressed this issue conducting retrospective, observational, multicenter study 632 patients subjected to peripheral blood HSCT at 20 Spanish centers. Monitoring DNA load plasma or whole was performed by real‐time PCR assays. Cumulative incidence DNAemia 48.9% (95% CI, 45%‐52.9%), any grade...